Prophylactic Minimally Invasive Surfactant Evaluation (PreProMISe)
Respiratory Distress Syndrome, Newborn, Premature Birth
About this trial
This is an interventional treatment trial for Respiratory Distress Syndrome, Newborn focused on measuring Respiratory Distress Syndrome, surfactant, Minimally invasive Surfactant Therapy
Eligibility Criteria
Inclusion Criteria: Gestational age <30 weeks Antenatal consent from Parent Exclusion Criteria: Congenital anomalies Alternate cause of respiratory distress
Sites / Locations
- Northshore University Healthsystem
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Prophylactic Surfactant via Minimally Invasive Technique
Rescue Surfactant via Minimally Invasive Technique
Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes).
The control group will be given surfactant will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.